London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Fund raise next!
That is a lot more shares
https://www.investegate.co.uk/okyo-pharma-ltd--okyo-/gnw/okyo-pharma-limited--160---okyo--or-the--company------160-conversion-of-clns--cashless-exercise-of-warrants--and-issue-of-equity/20220221170000H9126/
I would think the SP is sinking because if they do do a P2 trial a big fund raise will occur , diluting all share holders and take them into billions of shares. IMO
Am reasonably sure Zak tipped in in his 2021 list.
Why o Why is it falling. Cant see any negative in the RNS.
Infact, they are now fully focusing on 101.
The cash has gone down but isnt that already expected.
May buy more later.
What a dog of a share this is, just like the one the bods are attached to ( TILS) Tiziana Life Sciences
I have to second Bones warning. I am normally an optimist, but that has been dented by the Tweedle Dum and Tweedle Dee of Tiziana and Accustem, Gabriele Certone and Kunwar Shailubhai. OKYO belongs to the same stable of biotech startups of Gabriele's. I hope this product works out for OKYO but between now and trials in q3, the sp is only going one way without further news. And seeing how they have acted over at TiziAana that may be exactly what they want.
"13. Okyo Pharma (OKYO): 7p Target 20p
We stick with an unloved biotech for the next stock in the Top 20, much of which is based not only on the fundamental value behind a company, but also the acknowledgement that H2 2021 has been brutal as far as the small cap space has been concerned. We have been treated to delayed / overpriced IPOs, and stock margins being raised at the drop of a hat, something which quite understandably might have caused some to chance their arm in the wild west of crypto trading. For Okyo Pharma, 2022 looks to be a comeback year. It has been gestating its dry eye treatment, something which was well flagged in July with the tie up with Ora. It would appear that professional investors started appreciating what is to come from the early autumn, with the shares gapping up from 4p. Indeed, OK-101 is a wonderfully subtle and game changing treatment, able to bind to the surface of the eye, to target the inflammatory cells. One would assume that the reason that shares of Okyo are not much higher than they are is that investors have perhaps not taken the time to appreciate the advance that OKYO has made. Indeed, they have also not appreciated the recent announcements that not only has U.S. Patent issued for use of OK-101 to treat dry eye disease, but that OK-101 is to skip straight to Phase 2 human clinical trials in H2 next year. Given the size of the market, the breakthrough, and the strength of the IP, it can be said that genuine blockbuster drugs do not come much quicker, cheaper, or with greater application than the one that OKYO has under its wing."
I strongly advise anyone that’s considering investing here to check out Tiziana life sciences. The key players here such as Gabrielle Cerrone & Kunwar Shailubhai (recently stepped down) have missed enormous deadlines with no comment for the past 12 months, have demerger Another business (Accustem sciences) which still hasn’t listed for around 12 months & now have moved from the main market LSE listing to NASDAQ only and many uk shareholders still aren’t able to trade after around 55 days with the share price dropping daily & down around 80% since last year with no comment from the BOD or updates!
I would advise extreme caution here as the tactics were similar last year when the same people pumped Tiziana/TILS/TLSA with a pile of RNS then did a £57m raise & have since just disappeared really.
Spread the word
IND Q3 2022
Phase 2 trial Q4 2022 run by Ora.
Better late than never.
No comment from the AWOL chairman Gabriele Cerrone.
It get the feeling that something is going to happen soon. Price is trickling up and it has been so long since we had some proper news
Hello Cagney, I have had my tear ducts blocked and I use artificial tears but when they were really sore after having my first child - think it was hormone related (I’m a lady -Fred’s my lucky name)! my eyes kept getting infected and it’s like having sawdust in your eyes! But loads of conditions have dry eyes as a side effect.
Nice to see SP up today though!
aware what’s suddenly driven this up?
Hello Fred.What is the cause of your condition,it must be really sore and painful,what do you use to ease the problem?The body is so complicated,there's so many things that can go awry with it,so lets hope Okyo can become your knight in shinning armour.
I’ve got dry eyes that’s why I first invested and even though I’m currently under water I have a feeling about this share as well - dry eyes is a massive problem and really there is little out there that brings relief if you’ve really got dry eyes. Luckily mine aren’t as bad as they were thank goodness but a lot really struggle with this condition
I bought 300k of Okyo about two years ago at 1.99p,after reading that the funding they held was over subscribed by a good margin I decided to buy 140k more yesterday at 5.5,.There's a strong feeling in my water about this company.Feeling nothing more than feelings.
We have a background buyer
I got caught out on this a while back so certainly wouldn't enter it again and i hate to be negative
Dead cat bounce by MMs??
any idea what's going on?
Think the fact we’re up 27% up in last five days deserves a mention on this board! Nice to see - a long way to go though!
Well that's why you don't make as big a profit as you should, ha,ha.
nlondon1234
“ don't even know what it does.”
Well, the pigs have given each other some more buckets of swill. That’s always a red flag for me.